To identify more therapeutic targets and clarify the detailed mechanisms of Pseudomonas aeruginosa-mannosesensitive hemagglutinin (PA-MSHA) on breast cancer cells both in vitro and in vivo. PA-MSHA was administered to epidermal growth factor receptor (EGFR)-positive human breast cancer cell lines MDA-MB-231HM and MDA-MB-468 in vitro and to mice bearing tumor xenografts. The mannose cocultured test was used to detect the effect of mannose on PA-MSHA-induced cell proliferation, cell cycle arrest, apoptosis, and EGFR pathway signaling. We found that cells stimulated with PA-MSHA exhibited a downregulation of EGFR signaling. The addition of mannose partially inhibited the PA-MSHA-stimulated cell anti-proliferative effect, cell apoptosis, cell cycle arrest, activation of apoptosis-associated caspases, and even downregulation of the EGFR signaling pathway. In vivo, PA-MSHA treatment significantly suppressed mammary tumorigenesis in xenografts in mice and decreased lung metastasis in MDA-MB-231HM celltransplanted mice. Tumor sample analyses confirmed inhibition of the EGFR pathway in the PA-MSHAtreated mice. In conclusion, this study showed that the involvement of the mannose-mediated EGFR pathway has a critical function in the preclinical rationale for the development of PA-MSHA for the treatment of human breast cancer. It also suggests the potentially beneficial use of PA-MSHA in adjuvant therapy for breast tumors with EGFR overexpression.
Introduction
In recent studies, some new reagents with sugar-binding activity, which preferentially recognize oligosaccharides associated with several cell surface glycoconjugates, have been shown to have the potential to induce apoptosis in vitro in malignant cells (Wiest et al., 2003; Liu et al., 2009a, b) . In terms of sugar-binding activity, it has often been suggested that the adherence of live bacteria is mediated by type I fimbriae and can be inhibited by D-mannose (Duguid, 1968; Korhonen et al., 1980 Korhonen et al., , 1981 . The adhesion is mediated mainly by filamentous fimbriae expressed on the surface of the infectious organism that bind to complementary carbohydrates on the surface of the host tissue (Sharon, 2006) . The effect of hemagglutination caused by type 1 fimbriae is specifically blocked by D-mannose in a phenomenon called MSHA, mannose-sensitive hemagglutination. Lectin-like type 1 fimbriae are also responsible for the mannose-sensitive (binding) adhesion to host (mammalian) cells (Schilling et al., 2001; Duncan et al., 2005) . Such microbe-host protein-carbohydrate interaction (Karlsson, 2001 ) is not only the essential step to produce infection, but also it leads to a status alternation of the host cells, for instance, the induction of apoptosis (Mulvey et al., 1998; Klumpp et al., 2006) . Engineered bacteria are able to help control cancer (Jain and Forbes, 2001) . PA-MSHA is a genetically established, engineered Pseudomonas aeruginosa (PA) strain characterized by the expression of mannosesensitive type 1 fimbriae on its surface. In our earlier study, we reported that the biological response to the treatment with PA-MSHA includes an inhibition of cell proliferation, cell cycle arrest, and induction of apoptosis in human breast cancer cells compared with PA (Liu et al., 2009c) . This result suggests that the mannosesensitive type 1 fimbriae are responsible for the apoptosis and that a certain protein with high mannose expression that has a key role in mediating the growth of tumor cells might act as a potent ligand for those type 1 fimbriae.
The epidermal growth factor receptor (EGFR), also known as Her-1, has been identified as a transmembrane glycoprotein with high mannose expression. It has been shown to have an important function in the growth and survival of tumor cells, including processes such as cellular growth, apoptosis, metastasis, and angiogenesis (Zhang et al., 2007; Capdevila et al., 2009) . We have found that PA-MSHA preferentially inhibited the proliferation of breast cancer cell lines, which are all EGFR-positive. This finding may help us to identify more therapeutic targets and clarify the mechanism of the anti-proliferative effect of PA-MSHA. To do so, we assayed the EGFR signaling pathway, which is strongly associated with the cell proliferation signal transduction pathway and affects the chemosensitivity of tumor cells to anti-cancer agents. Our study was designed to investigate the biological therapeutic potential of PA-MSHA against breast carcinoma, to further define the functional mechanisms of PA-MSHA and to determine whether the EGFR pathway is involved in the apoptosis of breast cancer cells induced by PA-MSHA. Our results further support the potential for the clinical application of a PA-MHSA-based vaccine in future treatments of breast cancer.
Results
Changes in surface morphology accompanying PA-MSHA adhesion, which is mediated by a mannose-dependent manner Using scanning electron microscopy (SEM), we examined the surface morphology of PA-or PA-MSHA-treated cells (Figure 1 ). MDA-MB-231HM and MDA-MB-468 cells treated with phosphate-buffered saline (PBS) or 3.6 Â 10 8 cells/ml of PA were approximately spherical, exhibiting a round, smooth cell body without bacilliform material protuberances; they only possessed many thin, surface microvilli (Figures 1a, b, g, and h ). When MDA-MB-231HM cells were treated with 3.6 Â 10 8 cells/ml of PA-MSHA (Figures 1c and i ) for 24 h, SEM micrographs discovered a significant shrinkage of the cell body and far fewer microvilli. Most importantly, there were bacilliform materials (arrowheads) on the surface, interconnecting some of the cells, which were referred to morphologically as PA-MSHA. Similarly, this phenomenon was observed in cells treated with glucose-cocultured PA-MSHA (Figures 1d and j) . However, when cells were treated with mannosecocultured PA-MSHA, there were few rod-shaped bacteria found on the surface of the cells (Figures 1e  and k) . After 48 h, SEM micrographs discovered blebbing of the membrane surface (arrows) (Figures 1f  and l) .
Effect of mannose on the anti-proliferative effect of PA-MSHA When media containing 100 mM mannose were incubated with cells, the growth-inhibiting ability of PA-MSHA was weakened (Figure 2A , panels b and d). The IC 50 doses in MDA-MB-231HM and MDA-MB-468 cells treated with mannose-cocultured PA-MSHA (Table 1) were significantly higher than those that have been previously determined in sensitive cell lines. In contrast, as shown in Figure 2A (panels a and c), cell proliferation was not affected by incubation in the presence of the same concentrations of glucose. The IC 50 dose ranges for glucose-cocultured PA-MSHA were close to the IC 50 doses of the sensitive cell lines reported in our earlier study (Table 1) .
Effect of mannose on PA-MSHA-induced cell cycle arrest and apoptosis As shown in Figure 2B , cells stimulated with glucosecocultured PA-MSHA were considerably more sensitive to PA-MSHA-mediated G 0 -G 1 arrest. However, treatment with mannose-cocultured PA-MSHA restored the G 0 -G 1 phase to a relatively normal range. With regard to apoptosis, PBS or PA cocultured with mannose or glucose had little effect on apoptosis in MDA-MB-231HM and MDA-MB-468 cells. However, cells treated with mannose-cocultured PA-MSHA were more resistant to PA-MSHA-induced apoptosis than cells treated with glucose-cocultured PA-MSHA in both MDA-MB-231HM ( Figure 2C , panels a and b; 17 vs 9%, Po0.05) and MDA-MB-468 ( Figure 2C , panels a and b; 17 vs 10%, Po0.05) cells. We also tested the apoptotic morphological change in cell nuclei using Hoechst-33258. As shown in Figure 2D , treatment of the cells with 3.6 Â 10 8 cells/ml of PA-MSHA for 24 h with additional glucose in the coculture resulted in morphological changes that were distinguished by their characteristic patterns of apoptosis, whereas the addition of mannose to the culture medium with the same concentration of PA-MSHA exhibited a normal growth pattern.
Reversal of the proteolytic activities of pro-caspases is induced by PA-MSHA-coculture with mannose The addition of mannose partially inhibited the 3.6 Â 10 8. cells/ml of PA-MSHA-stimulated activation of caspases 3, 8, and 9 in both cell lines. As a result, neither MDA-MB-231HM nor MDA-MB-468 cells revealed further activation of all the caspases ( Figure 2E ), indicating that apoptosis was dramatically reduced. In contrast, the addition of glucose to the coculture did not change the effect of PA-MSHA. There was a loss of procaspases 3, 8, and 9 and also a significant increase in cleaved caspase protein.
PA-MSHA inhibits the EGFR signaling pathway
We tested whether treatment with PA-MSHA could reduce this basal EGFR phosphorylation. MDA-MB-231HM cells were incubated for 48 h in the presence of 1.8 Â 10 8 , 3.6 Â 10 8 , or 6 Â 10 8 cells/ml of PA-MSHA or 6 Â 10 8 cells/ml of PA as a control or PBS. Treatment with PA-MSHA caused a dose-dependent drop in pEGFR, pAKT, and pERK protein in the presence of EGF stimulation, whereas the total levels of EGFR, AKT, and ERK protein remained the same (Figure 3 ). Densitometry indicated that treatment with 1.8 Â 10 8 , 3.6 Â 10 8 , or 6Â 10 8 cells/ml of PA-MSHA caused decreases of 40, 76, and 90%, respectively, in phosphorylated EGFR. To verify that this effect was general, we analyzed one additional cell line, MDA-MB-468, and the results were similar (Figure 3 ). We repeated this experiment in the MCF-7 cell line, which was relatively resistant to PA-MSHA. As expected, PA-MSHA failed to reduce the pAKT and pERK protein levels in MCF-7 cells ( Figure 3 ).
Downregulation of EGFR may be involved in PA-MSHAinduced signal pathway regulation
To determine whether EGFR expression is critical for the effect of PA-MSHA on breast cancer cells in vitro, we next used specific genetic inhibition of EGFR to assess the consequences of its inhibition on PA-MSHAmediated signal pathway regulation. First, we confirmed that the two fragments of siRNA (EGFR-siRNA1 and EGFR-siRNA2) effectively reduced the EGFR protein level by B70% (Po0.05) in MDA-MB-231HM and MDA-MB-468 cells ( Figures 4A and B) . After transfection with siRNA targeting EGFR or control siRNA for 72 h, the cells were exposed to 3.6 Â 10 8 cells/ml of PA-MSHA or PA for 48 h. The reduction in pEGFR protein by siRNA resembled that seen with PA-MSHA ( Figure 4B ). However, reducing EGFR expression by Effect of EGFR knockdown on PA-MSHA-induced cell proliferation Silencing EGFR significantly decreased the cytotoxic effect of PA-MSHA on cells treated for 48 or 72 h compared with control-siRNA-transfected cells. We defined ratio1 as the OD values of the controlsiRNA þ PA-MSHA group relative to the OD values of the control-siRNA þ PA group, and ratio2 as the OD values of the EGFR-siRNA þ PA-MSHA group relative to the OD values of the EGFR-siRNA þ PA group. As shown in Figure 4E , panel a, ratio2 was significantly higher than ratio1. The results were similar when a PBS control was used ( Figure 4E, panel b) . PA-MSHA was notably unable to cause more cell death in cells transfected with EGFR siRNA.
PA-MSHA inhibits the invasive abilities of MDA-MB-231HM and MDA-MB-468 cells To investigate whether PA-MSHA could modulate the invasive abilities of MDA-MB-231HM and MDA-MB-468 cells in vitro, we assessed the expression level of some invasion-associated proteins in PA-MSHA-treated and parental cells. As shown in Figure 5A , PA-MSHAtreated cells have significantly lower expression levels of oncogenes VEGF, MMP-9, and Cathepsin-D and a significantly higher expression level of tumor-suppressor gene E-cadherin when compared with PA-or PBStreated cells. Also, we detected the amount of VEGF and MMP-9 in the conditioned cell supernatant by enzyme linked immunosorbent assay (ELISA). As a result, the levels of both VEGF and MMP-9 decreased in the PA-MSHA-treated cell supernatant ( Figure 5B ).
Effect of PA-MSHA on tumor growth and expansion of lung micrometastasis We further investigated the effect of PA-MSHA on a transplanted tumor growth produced by MDA-MB-231HM and MDA-MB-468 cells, and the formation of lung metastases by MDA-MB-231HM cells in mice. As shown in Figure 6A , the administration of PA-MSHA produced a 25 and 31% reduction in the tumor volume of MDA-MB-231HM and MDA-MB-468 cells, respectively. PA-MSHA caused a loss in the body weight of MDA-MB-231HM cell-and MDA-MB-468 cell-transplanted mice ( Figure 6B ), but the vitality of the mice was good. When compared with mice treated with PA or PBS, no sign of toxicity as judged by the parallel monitoring of body weight was observed in PA-MSHAtreated mice. Lung metastases were found in all PBS-, PA-, and PA-MSHA-treated mice ( Figure 6C , panels a-c). However, there was a trend toward significance between the PA-treated group and the PA-MSHAtreated group in the number of mice with lung metastases ( Figure 6C, panel d) . When compared with PA-treated mice, the mice treated with PA-MSHA showed a significant decrease in lung metastatic nodules and a significant decrease in the size of the lung metastatic nodules, with maximum reduction rates of B61 and 46%, respectively ( Figure 6C , panel e). We also extracted proteins from tumor xenografts to assess the levels of EGFR signaling pathway proteins. As shown in Figure 6D , decreases in pEGFR, pAKT, and pERK were observed in the tumors of PA-MSHAtreated mice. In addition, we measured the amounts of VEGF and MMP-9 in the mice serum by ELISA. The 
Discussion
In this study, we sought to prove that the attachment of PA-MSHA, a genetically engineered bacterium, to target cells depends on the availability of receptors and the sugar-binding activity of PA-MSHA. We reviewed the published literature and found that there was strong evidence for a positive link between adherence, the presence of fimbriae, and mannosebinding activity by bacteria (Harper et al., 1978; Ofek and Beachey, 1978; Sharon, 1987 Sharon, , 2006 . For several (Stepinska and Trafny, 1995; King et al., 2000; McEwan et al., 2008) . Earlier studies have shown that at least three different types of lectin-like proteins are responsible for the attachment of the saccharide structures of epithelial cells to the adherence proteins of gram-negative bacteria, which are mediated in a mannose-sensitive manner. Bacteria whose adhesion is inhibited in the presence of mannose are defined as carriers of type 1 fimbriae, and their adherence seems to be mediated mainly by the type 1 bacterial fimbriae (Duguid, 1968) . Fimbriae isolated from PA-MSHA, a kind of peritrichous PA strain with MSHA fimbriae, contain one class of lectin-like proteins comprising the bacterial fimbriae (also known as type 1 fimbriae), which were previously shown to facilitate the mannose-sensitive adherence of various bacteria to mammalian cells (Eshdat and Sharon, 1984) . As shown in Figure 1 , the SEM results from our study yielded discoveries that further supported this hypothesis. Unlike heat-killed PA, PA-MSHA can recognize and bind to the mannose residue of glycoproteins on the surface of cells. Therefore, the mannose-sensitive adherence of PA-MSHA may be mediated by lectin-like proteins associated with the fimbriae located on the outer bacterial membrane, which can be inhibited with mannose.
To identify whether the induction of apoptosis by PA-MSHA was also mannose-sensitive, we used the optimal inhibitory activity of 100 mM D-mannose (B2%) to try to inhibit the adherence of PA-MSHA. On the basis of our results (Figure 2 ), the addition of mannose partially inhibited the PA-MSHA-stimulated cell anti-proliferation, cell apoptosis, cell cycle arrest, and activation of apoptosis-associated caspases. As a negative control, glucose does not seem to be involved in the sugarbinding activity of MSHA during coculture. Therefore, the difference in the effects between mannose and glucose suggests that the apoptosis induced by PA-MSHA is mannose-sensitive. This may indicate that the critical effective pharmacological site of PA-MSHA, which is located in the fimbrium and is characterized by a mannose-sensitive binding protein, can specifically conjugate with the mannose-rich surface of the highmannose type of tumor cells. In addition to the lectin-like activities associated with fimbriae, our studies show for the first time the ability of PA-MSHA to ablate the EGFR signaling cascade in breast cancer cells overexpressing EGFR by reducing basal EGFR phosphorylation (Figure 3) . In contrast, PA-MSHA failed to reduce EGFR signaling pathway levels in MCF-7 breast cancer cells that displayed relatively low levels of EGFR protein (Hoadley et al., 2007) . Reducing EGFR expression by transfecting cells with EGFR siRNA had no effect on PA-MSHAinduced EGFR signaling pathway regulation (Supplementary Figure 1) . We have also shown that the EGFRnegative cell line MCF-7 was relatively resistant to PA-MSHA. The ability of PA-MSHA to induce apoptosis in malignant tumor cells seems to indicate that the EGFRdependent mechanism might be the major mode of inducing apoptosis.
Studies have reported that EGFR contains a large number of mannose oligosaccharides (Johns et al., 2005; Kawashima et al., 2009) , which probably account for the binding of the cell surface to PA-MSHA. The immature high-mannose form of EGFR reaches the cell surface in cells overexpressing the receptor (Helenius and Aebi, 2001; Johns et al., 2005) . The incompletely glycosylated immature high-mannose form located on the surface of tumor cells overexpressing EGFR loses the ability to suppress the spontaneous dimerization of EGF receptors, which leads to auto-and crossphosphorylation of the receptors and further propagation of the signal. As verified by our results, when additional 100 mM mannose was added to the PA-MSHA medium, the ability of PA-MSHA to induce EGFR signal pathway regulation was weakened (Supplementary Figure 2) , indicating that the downregulation of the EGFR signaling pathway induced by PA-MSHA is mannose-sensitive. PA-MSHA may preferentially recognize EGF receptors containing highmannose oligosaccharides and affect the formation of EGFR dimers as a result. Therefore, it is not surprising that cell lines overexpressing EGFR were most affected by and most sensitive to PA-MSHA because of the highmannose glycoforms of EGFR. We proposed the hypothesis that PA-MSHA binds to the surface highmannose carbohydrates and either blocks the activities of the glycoside responsible for the dimerization or prevents the next step of phosphorylation of the EGF receptors on the surface of tumor cells.
Systemic administration of PA-MSHA in MDA-MB-231HM and MDA-MB-468 xenotransplanted nude mice confirmed the inhibitory effect of PA-MSHA on breast cancer. PA-MSHA might prove to be a novel, nontoxic, water-soluble biological therapeutic agent for human breast cancer. In addition, our results proved that PA-MSHA may affect the invasive and metastatic phenotypes of breast cancer cells. However, more experiments are needed to validate these results.
In previously published literature, downregulation of EGFR signaling pathway predisposed cells to apoptosis. Apoptosis has also been proven to be prominently increased in EGFR anti-sense-or siRNA-treated groups, indicating that EGFR is an important way to induce the cascade-dependent apoptosis (Schaerli and Jaggi, 1998; Gibson et al., 1999; Lage et al., 2003; Kang et al., 2006) . Our study discovered several novel concepts for biological therapy. The first is that PA-MSHA can inhibit the EGFR pathway signaling in a mannosesensitive manner. The second is that the adhesion of PA-MSHA via type 1 fimbriae to glycoproteins located on the surface of cells is mannose-sensitive. Finally, the PA-MSHA-mediated apoptosis and boosting of the caspase-signaling cascade is a mannose-related cellsignaling pathway. Altogether, the most likely sequence of events responsible for PA-MSHA-induced apoptosis in MDA-MB-231HM and MDA-MB-468 cells begins with recognition and binding of the bacterial fimbriae (also known as type 1 fimbriae) of PA-MSHA to the mannose residue of glycoproteins (mainly the EGF receptors) on the surface of cells. This causes a significant decrease in the level of phosphorylated EGFR, which leads to and increases the activation of caspase-9 and caspase-8, which in turn activates caspase-3 and eventually induces apoptosis. As PA-MSHA uses the sugar-binding characteristics of cancer cells, treatments that target multiple sugars may be an attractive prospect, particularly as a new target of cancer therapy. PA-MSHA could be used as a novel candidate agent in the treatment of cancer in the near future. By making good use of microorganisms, we can succeed in suppressing tumor growth, reversing its development and, in some cases, curing the organism.
Materials and methods

Cell lines and materials
The human breast cancer cell lines MCF-7, MDA-MB-231HM, and MDA-MB-468 used were obtained in the same way and grown in the same medium as we have reported earlier (Liu et al., 2009c) . The PA-MSHA and inactivated PA used in this study was the same as that used in our previous study. PBS (0.1 M, GIBCO, Grand Island, NY, USA) was used as a blank control. The following reagents and primary antibodies were used: anti-phospho-EGFR (pEGFR), anti-ERK (tERK), anti-phospho-ERK (pERK), anti-AKT (tAKT), anti-phospho-AKT (pAKT), anti-caspase 3, anticleaved caspase 3, anti-caspase 8, anti-cleaved caspase 8, anticaspase 9, anti-cleaved caspase 9 (Cell Signaling Technology, Danvers, MA, USA), anti-EGFR (tEGFR), anti-Cathepsin-D, anti-VEGF, anti-MMP9, anti-E-cadherin, and anti-GAPDH (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Human recombinant EGF and Lipofectamine 2000 reagent were obtained from Mukilteo, WA, USA) and Invitrogen (Carlsbad, CA) (Cat. No 11668-019), respectively.
Mannose or glucose coculture test D-mannose (Sigma, G8644, St Louis, MO, USA) was added to a final concentration of 100 mM in the PA-MSHA suspension, or the assay was carried out with 100 mM D-glucose (Sigma, M6020) in the PA-MSHA suspension to serve as a control. PA-MSHA and PA stock solution were both preincubated with 100 mM mannose or 100 mM glucose for 24 h. PA-MSHA or PA was then washed three times with fresh medium before coculture with cells. PA-MSHA or PA were transferred to fresh cultures of breast cancer cell lines or fresh medium, supplemented with 100 mM mannose or 100 mM glucose. These cocultures were performed before the supernatants were removed for further analysis.
Scanning electron microscopy
For SEM, cells were treated with 3.6 Â 10 8 cells/ml of PA or PA-MSHA and then washed twice with PBS. They were cultured on glass coverslips and fixed in cold 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.3). After several washes with 0.1 M sodium cacodylate containing 2% sucrose, cells were postfixed with 0.1% osmium tetroxide in 0.2 M sodium cacodylate for 30 min. Specimens were dehydrated in an ethanol series and dried to the critical point. After sputter-coating with gold-palladium, the samples were examined under a Hitachi S-570 Scanning Electron Microscope (Hitachi, Tokyo, Japan).
Cell proliferation
Cytotoxic effects of PA-MSHA or PA on the cells were evaluated by the Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies Inc., Gaithersburg, MD, USA) assays as mentioned in the previous study (Liu et al., 2009c) . Cells were treated with several specified concentrations of PA-MSHA or PA cocultured with 100 mM mannose or 100 mM glucose and then incubated at 37 1C for another 24, 48, or 72 h. The IC 50 value was calculated using CalcuSyn Software (Biosoft, Ferguson, MO, USA).
Flow cytometry with annexin V-FITC and PI staining Cells were pretreated with solution containing 100 mM mannose or glucose-incubated PA (3 Â 10 8 cells/ml), PA-MSHA (3 Â 10 8 cells/ml), or PBS control for 24 h and single-cell suspensions containing at least 1 Â 10 6 cells were prepared. Cell cycle and apoptotic analyses were performed by flow cytometry (FCM) as previously described using an FACScalibur system (Wang et al., 2008) . Apoptotic cells were analyzed by quadrant statistics of the propidium iodidenegative and annexin V-positive cells.
Morphological measurement of apoptosis
Cells were treated with the appropriate mannose or glucose cocultured drugs (PA-MSHA or PA at 3.6 Â 10 8 cells/ml or PBS) for 24 h, stained with 5 mg/l Hoechst 33258 (Sigma) for 30 min at 37 1C and then visualized under a fluorescence microscope with standard excitation filters. The apoptotic cells were visualized at 400 Â magnification.
Western blotting
For detection of the EGFR signaling pathway and metastasisassociated proteins, cells were starved in medium containing 1% FBS for 24 h; they were treated with either 6 Â 10 8 cells/ml of PA or 0, 1.8, 3.6, or 6 Â 10 8 cells/ml of PA-MSHA in medium containing 1% FBS for 48 h. The cells were then stimulated with 5 ng/ml EGF (still in the presence of PA or PA-MSHA) for 10 min. Cells were treated with the mannose or glucose coculture test as mentioned above. Then, the wholecell lysates were collected following the standardized protocol as described in an earlier study (Liu et al., 2009c) . A densitometry analysis was performed with Quantity One software (BioRad, Hercules, CA, USA). The relative expression level of each protein was normalized by dividing the level of target protein by the level of GAPDH for each sample.
RNA interference siRNAs against EGFR were transfected into MDA-MB-231HM and MDA-MB-468 cells, which expressed a high level of EGFR, according to the transfection protocol of Lipofectamine 2000 (Invitrogen) . siRNAs against the following EGFR sense strand sequences were transfected individually (100 nM): EGFR-siRNA1, sense 5 0 -UGA UCU GUC ACC ACA UAA UUA CGG G-3 0 (EGFR-HSS103114); EGFRsiRNA2, sense 5 0 -AUA CCU AUU CCG UUA CAC ACU UUG C-3 0 (EGFR-HSS103115). A nonspecific control siRNA strand (control-siRNA, sense 5 0 -GGA GCU GCC CAU GAG AAA UUU-3 0 ) was used as a negative control. Seventy-two hours after transfection, knockdown was assessed by western blot from a parallel transfection. To assess the effect of PA-MSHA on cell proliferation after EGFR-siRNA transfection, cells were transfected with siRNAs for 72 h. Fresh medium containing 1% FBS and 6 Â 10 8 cells/ml of PA-MSHA or PA or PBS was added; the cells were then incubated at 37 1C for another 48 or 72 h. The inhibition of cell growth was determined by CCK-8 assays. To detect the effect of EGFR-siRNA on the PA-MSHA-induced downregulation of tAKT, pAKT, tERK, and pERK levels, cells were transfected with EGFR-siRNA or control-siRNA for 72 h and then treated with 3.6 Â 10 8 cells/ml of PA-MSHA or PA before western blot detection.
ELISA analysis
After cells were treated with 0, 1.8, 3.6, or 6 Â 10 8 cells/ml of PA-MSHA, 6 Â 10 8 cells/ml of PA or PBS for 24 h, an equal number of cells was seeded into six-well plates. Cells were washed three times and allowed to condition the medium for another 24 h. The levels of human VEGF and MMP-9 protein accumulating in the medium were determined using an ELISA kit (Human VEGF SX01176, Human MMP-9 SX01113 immunoassay kit, R&D Systems Inc., Minneapolis, MN, USA). In addition, the amounts of mouse VEGF and MMP-9 in PA-MSHA-treated PA-treated MDA-MB-231HM and MDA-MB-468 5-week xenografts were also determined by an ELISA kit (Mouse VEGF SXR068, Mouse MMP9 SXR049 immunoassay kit, R&D Systems Inc.) in duplicate according to the manufacturer's instructions.
In vivo tumor xenograft study Four-to six-week-old female BALB/c-nu/nu nude mice were purchased from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (Shanghai, China). Tumors were initiated by s.c. injection of 5 Â 10 6 cells into the right mammary fat pad of the nude mice. The mice were randomized and assigned to the control group or the experimental group. Mice in the control group were given 0.1 ml PBS or 0.1 ml PA (2.2 Â 10 10 cells/ml) s.c. treatment daily and mice in the PA-MSHA group were given 0.1 ml PA-MSHA (2.2 Â 10 10 cells/ml) s.c. treatment daily. The tumors were measured twice a week with microcalipers and tumor volume was measured using the formula p/6 Â larger diameter Â (smaller diameter) 2 . Also, the body weight of the animals was recorded twice a week. At the end of the experiment, trunk blood was collected and the serum was separated and analyzed by ELISA. Tumors were dissected and snap-frozen for molecular biology analyses. Total protein was extracted from the tumors to quantify the level of the protein by western blot. The metastasis was identified in the lung, and the numbers of metastatic tumor nodules were counted.
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) software version 15 for Windows (SPSS Inc., Chicago, IL, USA). Student's t-tests were used to determine the statistical significance of the differences between the experimental groups. A P-value of o0.05 was considered significant. Graphs were created using Microcal Origin software (version 3.78; Microcal Software Inc., Northampton, MA, USA).
